On April 1, 2025 Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, reported that the Company’s CEO, Gil Efron will participate in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7, 2025 (Press release, Purple Biotech, APR 1, 2025, View Source [SID1234651722]). The panel titled "New Radiotherapy and Targeted Therapy Approaches" will take place from 2:00 PM to 2:50 PM ET. Management will also participate in 1×1 meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!